

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi.  
We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

**Cais Rhyddid Gwybodaeth / Freedom of Information request**  
**Ein Cyf / Our Ref: 22-G-003**

**You asked:**

Please complete the table below:

<b>Radium-223 dichloride service</b>	
<b>Is radium-223 dichloride offered in your Health Board as a treatment for prostate cancer? (y/n)</b>	No – suitable patients are referred to Bristol Royal Infirmary via our Prior Approval process.
<b>If yes, please list the indications for which it is used in your Health Board?</b>	n/a

**Question 2**

**Please detail the number of patients that are treated with radium-223 dichloride in your Health Board:**

<b>Patient numbers</b>	
<b>Number of prostate cancer patients completing treatment with radium-223 dichloride per year</b>	n/a
<b>Number of prostate cancer patients initiating radium-223 dichloride treatment per year</b>	n/a



<b>What is the average number of cycles administered per patient in your service?</b>	n/a
<b>What is the waiting time before patients can receive radium-223 dichloride?</b>	n/a
<b>How many patients are initiated with cabazitaxel per year in your Health Board?</b>	n/a

### Question 3

**In what department is molecular radiotherapy provided in your Health Board?**

<b>Administration</b>	<b>Radium-223 dichloride</b>	<b><sup>177</sup>Lutetium based radioligand therapy for neuroendocrine tumours</b>
<b>Nuclear Medicine</b>		
<b>Medical Physics</b>		
<b>Radiotherapy</b>		
<b>Oncology</b>		
<b>Urology</b>		
<b>Other</b>		
<b>N/A</b>	X	X – this service is not NICE approved and is not offered in Wales

### Question 4

**What codes are associated with molecular radiotherapy administration in your Health Board?**

<b>NHS codes</b>	HRG	OPCS code
------------------	-----	-----------



Radium-223 dichloride	n/a	n/a
-----------------------	-----	-----

### Question 5

Please complete the table below:

Who performs the administration of the treatment?	Radium-223 dichloride	<sup>177</sup> Lutetium based radioligand therapy for neuroendocrine tumours
<b>CNS</b>	n/a	n/a
<b>Technician</b>	n/a	n/a
<b>NM nurse</b>	n/a	n/a
<b>NM physicist</b>	n/a	n/a
<b>NM Consultant</b>	n/a	n/a
<b>Oncologist</b>	n/a	n/a
<b>Other (please state)</b>	n/a	n/a

### Question 6

Who holds the ARSAC licence in your Health Board?

Administration	(y/n)	Radium-223 dichloride	<sup>177</sup> Lutetium based radioligand therapy for neuroendocrine tumours
<b>Nuclear Medicine consultant</b>	n/a	n/a	n/a
<b>Clinical Oncologist</b>	n/a	n/a	n/a
<b>Radiologist</b>	n/a	n/a	n/a



<b>Other (please state speciality)</b>	n/a	n/a	n/a
--	-----	-----	-----

### Question 7

**Do you provide Radioactive Waste Advisory, Radiation Protection Advisory and Medical Physics Expert services in your Health Board or are they outsourced?**

<b>Radiation safety (y/n)</b>	<b>Conducted in-house (If so, please provide the number of full-time equivalents providing these services in your centre)</b>	<b>Outsourced</b>
<b>Radioactive Waste Adviser (RWA)</b>	1 WTE	n/a
<b>Radiation Protection Adviser (RPA)</b>	2 WTE	n/a
<b>Medical Physics Expert (MPE)</b>	6 WTE (Nuclear Medicine and Radiation Physics, excluding Radiotherapy)	n/a

### Question 8

**Please complete the table below:**

<b>Dosimetry</b>	<b>(y/n)</b>	<b>If yes, what is the schedule after each administration?</b>	<b>If yes, is this analysed in-house or outsourced?</b>
<b>Is dosimetry performed for radium-223 dichloride prostate cancer patients?</b>	n/a	n/a	n/a

